Drug Trial Radar · NCT06489015
Recombinant Human Serum Albumin in the Treatment of Mild-to-moderate AD (Alzheimer's Disease) Exploratory Clinical Trial
Last checked: Nov 20, 2026Latest source record: Aug 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Aug 27, 2024
Primary completion
Apr 14, 2026
Study completion Apr 14, 2026
Sponsor
- Lead sponsor
- Shenzhen Protgen Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 5, 2024
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is an open-label, parallel-group, exploratory study of recombinant human serum albumin in patients with mild to moderate Alzheimer's Disease (AD).
Conditions
- Alzheimer's Disease (AD)
Interventions
Recombinant Human Serum AlbuminDrug
Each group receives the investigational drug (recombinant human serum albumin), with the distinction being the variation in dosing.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventsTime frame: About week 29 or 41(It depends on whether the participant enters the extention treatment period)
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Luoyang Third People's Hospital
Luoyang, Henan, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Wuhan Union Hospital of China
Wuhan, Hubei, China
Clinical Medical College & Affiliated Hospital Of Jiujiang University
Jiujiang, Jiangxi, China
Shanghai Mental Health Center
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.